Applied DNA Sciences Inc (APDN): Price and Financial Metrics
APDN Price/Volume Stats
Current price | $0.41 | 52-week high | $1.86 |
Prev. close | $0.43 | 52-week low | $0.37 |
Day low | $0.41 | Volume | 50,400 |
Day high | $0.45 | Avg. volume | 107,502 |
50-day MA | $0.56 | Dividend yield | N/A |
200-day MA | $0.97 | Market Cap | 6.96M |
APDN Stock Price Chart Interactive Chart >
APDN Stock Summary
- APPLIED DNA SCIENCES INC's market capitalization of $8,609,387 is ahead of just 4.57% of US-listed equities.
- For APDN, its debt to operating expenses ratio is greater than that reported by just 12.54% of US equities we're observing.
- As for revenue growth, note that APDN's revenue has grown -26.43% over the past 12 months; that beats the revenue growth of merely 10.48% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to APPLIED DNA SCIENCES INC, a group of peers worth examining would be GNSS, NURO, RPID, TIVC, and KRMD.
- APDN's SEC filings can be seen here. And to visit APPLIED DNA SCIENCES INC's official web site, go to www.adnas.com.
APDN Valuation Summary
- In comparison to the median Healthcare stock, APDN's EV/EBIT ratio is 101.37% lower, now standing at -0.2.
- Over the past 214 months, APDN's EV/EBIT ratio has gone up 41.8.
Below are key valuation metrics over time for APDN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
APDN | 2023-12-29 | 0.6 | 1.7 | -0.8 | -0.2 |
APDN | 2023-12-28 | 0.7 | 1.8 | -0.9 | -0.2 |
APDN | 2023-12-27 | 0.6 | 1.7 | -0.9 | -0.2 |
APDN | 2023-12-26 | 0.6 | 1.7 | -0.9 | -0.2 |
APDN | 2023-12-22 | 0.6 | 1.7 | -0.9 | -0.2 |
APDN | 2023-12-21 | 0.6 | 1.6 | -0.8 | -0.1 |
APDN Growth Metrics
- Its 3 year price growth rate is now at -95.34%.
- Its year over year net income to common stockholders growth rate is now at -5.91%.
- Its year over year cash and equivalents growth rate is now at -52.87%.
The table below shows APDN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 19.26572 | -7.657918 | -7.499602 |
2022-09-30 | 18.16868 | -8.976706 | -8.377996 |
2022-06-30 | 17.64909 | -10.43016 | -12.22587 |
2022-03-31 | 15.05304 | -9.92572 | -14.55064 |
2021-12-31 | 11.5773 | -12.93411 | -14.19865 |
2021-09-30 | 9.027738 | -13.38795 | -14.28644 |
APDN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- APDN has a Quality Grade of D, ranking ahead of 5.38% of graded US stocks.
- APDN's asset turnover comes in at 0.427 -- ranking 359th of 563 Business Services stocks.
- GRNQ, VOLT, and FC are the stocks whose asset turnover ratios are most correlated with APDN.
The table below shows APDN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.427 | 0.793 | -5.931 |
2021-03-31 | 0.361 | 0.820 | -6.288 |
2020-12-31 | 0.252 | 0.749 | -9.825 |
2020-09-30 | 0.163 | 0.627 | -10.610 |
2020-06-30 | 0.331 | 0.731 | -7.330 |
2020-03-31 | 0.683 | 0.796 | -6.300 |
APDN Price Target
For more insight on analysts targets of APDN, see our APDN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $17.67 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Applied DNA Sciences Inc (APDN) Company Bio
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications and can be used to fortify brand protection efforts, and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide definitive real-time authentication of molecular tags in the field; and CertainT Supply Chain Platform that provides proof of product claims for materials, items, or products. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19 in defined populations under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Latest APDN News From Around the Web
Below are the latest news stories about APPLIED DNA SCIENCES INC that investors may wish to consider to help them evaluate APDN as an investment opportunity.
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow- Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with Mitigated dsRNA and Reduced Turnaround Times -STONY BROOK, NY and NEEDHAM, MA / ACCESSWIRE / December 14, 2023 / Applied ... |
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2023 Earnings Call TranscriptApplied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2023 Earnings Call Transcript December 8, 2023 Operator: Good Day and welcome to the Applied DNA Sciences Fiscal Fourth Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Sanjay Hurry, Head of Investor […] |
Applied DNA Sciences, Inc. (APDN) Q4 2023 Earnings Call TranscriptApplied DNA Sciences, Inc. (APDN) Q4 2023 Earnings Conference Call December 07, 2023 04:30 PM ET Company Participants Sanjay Hurry - Head of IR Beth Jantzen - CFO James Hayward - Chairman, President and CEO Clay Shorrock - Chief Legal Officer and Head of Business Development Conference Call Participants Jason McCarthy - Maxim Group Yi Chen - H.C. Wainwright Presentation Operator Good Day and welcome to the Applied DNA Sciences Fiscal Fourth Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Sanjay Hurry, Head of Investor Rela... |
APDN Stock Earnings: Applied DNA Sciences Beats EPS, Misses Revenue for Q4 2023APDN stock results show that Applied DNA Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. |
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results- Conference Call/Webcast Scheduled for Today at 4:30 PM ET -STONY BROOK, NY / ACCESSWIRE / December 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated ... |
APDN Price Returns
1-mo | -31.21% |
3-mo | -33.53% |
6-mo | -66.12% |
1-year | -64.35% |
3-year | -94.23% |
5-year | -98.56% |
YTD | -33.53% |
2023 | -62.84% |
2022 | -58.71% |
2021 | -21.18% |
2020 | 21.72% |
2019 | -73.81% |
Continue Researching APDN
Want to see what other sources are saying about Applied Dna Sciences Inc's financials and stock price? Try the links below:Applied Dna Sciences Inc (APDN) Stock Price | Nasdaq
Applied Dna Sciences Inc (APDN) Stock Quote, History and News - Yahoo Finance
Applied Dna Sciences Inc (APDN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...